Interview with Gordon Bates, Head of Operations and Site Manager, Lonza UK
Can you provide us with an overview of what the UK market represents for the greater Lonza group? Lonza Biologics…
Lonza UK
Last updated: 13.02.2014
Address: 228 Bath Road, Slough, Berkshire, SL1 4DX, Great Britain,United Kingdom
Tel: +44 1753 777000
Company description
Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Products and services
To provide optimal support to our customers, we are organized in businesses that focus on specific sets of customers and their exact needs. We operate as three divisions: Life Science ingredients, Custom Manufacturing and Bioscience.
Interviews
Related
M&A / Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for Cannabinoid Research
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
UK / New Post-Brexit Regulatory Alliance with Australia, Canada, Singapore & Switzerland
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
UK-Japan FTA / Banishing UK Pharma's Brexit Blues
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
UK / MSD to Build USD 1.3 Billion London Research Hub in Boon for Post-Brexit Britain
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Opinion / 3 Ways the UK’s Pharma Sector is Driving Innovation
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical…
News Roundup / UK Pharma May 2020
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British…
Coronavirus / GSK & Sanofi’s Unprecedented COVID-19 Vaccine Collaboration
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…
The UK / The G7’s Hottest Life Science Investment Destination?
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is…
Brexit / Uncertainty Still Reigns for UK Life Sciences
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British…
Biotech Funding / 2019 A Boom Year for UK Biotech, Despite Brexit Concerns
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019…
Cannabis / GW Pharma's CBD Drug Profits Soar in 2nd Quarter 2019
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019,…
Amryt: A Rare Disease Startup Going Global
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial…
